Back to Healio The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two or three is ending early due to robust positive evidence ...

This decision suggests that Winrevair has shown significant benefits for patients with pulmonary arterial hypertension, which was initially observed in the STELLAR trial. Graybosch believes that ...

Developing greener alternatives for industrial chemicals that have a smaller impact on the environment isn't always ...

A biomaterial that can mimic certain behaviors within biological tissues could advance regenerative medicine, disease modeling, soft robotics and more, according to researchers.

The way the body ages could be more resilient than previously thought, a new study suggests.

Winrevair generated $200M Get the Real Story Behind Every Major Earnings Report Merck reported adjusted EPS of $1.72, up from $0.03 a year ago and beating the consensus of $1.62. Lower charges for ...

Chief Executive Robert Davis attributed growth in 2024 to Keytruda, the launch of Winrevair and performance in the animal health business. Winrevair launched in the U.S. in the second quarter.

Researchers have created a recyclable, bio-based alternative to thermoset plastics using dihydrofuran (DHF). Cornell ...

After slow rollout, Merck's Winrevair poised for 'strong uptake' in 2025: Leerink Additionally, Merck continues to maintain faith in Gardasil’s future sales prospects in China overall ...

Higher sales in the cardiovascular franchise, according to Merck, reflecting the successful launch of WINREVAIR, as well as higher sales of certain hospital acute care products, particularly ...